Plus Therapeutics (PSTV) Fundamental Analysis: Revenue, Earnings & Valuation

9.70 / 10

Outperform

Fundamental assessment rates PSTV at 9.7/10 (Outperform). Key strengths include high inventory turnover (34.35), solid current (0.0108) and fixed asset turnover (0.1599), and a 100% gross margin. Cost of sales is high (92.4%) and tax ratio modest (8.35%).

Analysis Checks(4/6)

Inventory turnover ratio

Value34.35

Score2/3

Weight-195.78%

1M Return-0.56%

Gross profit margin (%)

Value100.00

Score1/3

Weight125.47%

1M Return0.36%

Income tax / Total profit (%)

Value8.35

Score1/3

Weight74.54%

1M Return0.21%

Current assets turnover ratio

Value0.01

Score2/3

Weight696.55%

1M Return1.91%

Fixed assets turnover ratio

Value0.16

Score3/3

Weight643.20%

1M Return1.76%

Cost of sales ratio (%)

Value92.41

Score2/3

Weight-1243.98%

1M Return-3.62%

Is PSTV undervalued or overvalued?

PSTV scores 9.70/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.00% ROE, -429.43% net margin, -1.86 P/E ratio, 10.43 P/B ratio, and 85.13% earnings growth, these metrics solidify its Outperform investment rating.